ATE484508T1 - Furylverbindungen - Google Patents

Furylverbindungen

Info

Publication number
ATE484508T1
ATE484508T1 AT03746523T AT03746523T ATE484508T1 AT E484508 T1 ATE484508 T1 AT E484508T1 AT 03746523 T AT03746523 T AT 03746523T AT 03746523 T AT03746523 T AT 03746523T AT E484508 T1 ATE484508 T1 AT E484508T1
Authority
AT
Austria
Prior art keywords
compounds
furyl compounds
furyl
compositions
therapy
Prior art date
Application number
AT03746523T
Other languages
English (en)
Inventor
Hui-Fang Chang
Yan Li
Eifion Phillips
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201186A external-priority patent/SE0201186D0/xx
Priority claimed from SE0203607A external-priority patent/SE0203607D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE484508T1 publication Critical patent/ATE484508T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03746523T 2002-04-18 2003-04-15 Furylverbindungen ATE484508T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201186A SE0201186D0 (sv) 2002-04-18 2002-04-18 Furyl compounds
SE0203607A SE0203607D0 (sv) 2002-12-04 2002-12-04 Furyl compounds
PCT/SE2003/000613 WO2003087102A1 (en) 2002-04-18 2003-04-15 Furyl compounds

Publications (1)

Publication Number Publication Date
ATE484508T1 true ATE484508T1 (de) 2010-10-15

Family

ID=29253788

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03746523T ATE484508T1 (de) 2002-04-18 2003-04-15 Furylverbindungen

Country Status (15)

Country Link
US (1) US7417049B2 (de)
EP (1) EP1499618B1 (de)
JP (1) JP4511195B2 (de)
KR (1) KR20040099447A (de)
CN (1) CN1325500C (de)
AT (1) ATE484508T1 (de)
AU (1) AU2003225456B2 (de)
BR (1) BR0309343A (de)
CA (1) CA2482311C (de)
DE (1) DE60334536D1 (de)
IL (1) IL164509A0 (de)
MX (1) MXPA04010191A (de)
NO (1) NO20044996L (de)
NZ (1) NZ561794A (de)
WO (1) WO2003087102A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
CZ2004408A3 (cs) 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0309342A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
JP4855264B2 (ja) * 2003-10-21 2012-01-18 アストラゼネカ・アクチエボラーグ スピロフロピリジンアリール誘導体
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
RU2582339C2 (ru) * 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US10174052B2 (en) 2014-11-04 2019-01-08 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
CN108003895B (zh) * 2016-10-28 2019-04-19 西安近代化学研究所 一种向列相液晶组合物及其显示元件
CN108018049B (zh) * 2016-10-28 2019-09-27 西安近代化学研究所 具有5,6-二氟取代苯并呋喃环的液晶化合物
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
ES3030701T3 (en) 2018-05-10 2025-07-01 Zoetis Services Llc Endoparasitic depsipeptides
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
WO2002096912A1 (en) * 2001-06-01 2002-12-05 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
BR0309342A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas

Also Published As

Publication number Publication date
EP1499618B1 (de) 2010-10-13
JP4511195B2 (ja) 2010-07-28
JP2005533012A (ja) 2005-11-04
NO20044996L (no) 2005-01-18
IL164509A0 (en) 2005-12-18
HK1079519A1 (en) 2006-04-07
MXPA04010191A (es) 2005-02-03
EP1499618A1 (de) 2005-01-26
US20050176745A1 (en) 2005-08-11
CA2482311C (en) 2009-12-08
KR20040099447A (ko) 2004-11-26
BR0309343A (pt) 2005-02-15
NZ561794A (en) 2008-11-28
WO2003087102A1 (en) 2003-10-23
US7417049B2 (en) 2008-08-26
AU2003225456B2 (en) 2009-02-05
CA2482311A1 (en) 2003-10-23
CN1325500C (zh) 2007-07-11
AU2003225456A1 (en) 2003-10-27
DE60334536D1 (de) 2010-11-25
CN1662541A (zh) 2005-08-31

Similar Documents

Publication Publication Date Title
DE60334536D1 (de) Furylverbindungen
NO20044995L (no) Heterosykliske forbindelser
ATE477256T1 (de) Thienylverbindungen
SE0401971D0 (sv) Piperidne derivatives
SE0101387D0 (sv) Novel compounds
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
SE0202463D0 (sv) Novel compounds
SE0401970D0 (sv) Novel compounds
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
MX2007005933A (es) Compuestos de acetamida como fungicidas.
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
SE0302139D0 (sv) Novel compounds
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
ATE452896T1 (de) C3-cyanoepothilonderivate
SE0203303D0 (sv) Novel Compounds
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
SE0203302D0 (sv) Novel Compounds
NO20030500L (no) Dihydroporfyrinderivater og deres anvendelse
EA200600092A1 (ru) Новые цитотоксические депсипептиды
DK1638948T3 (da) Diphenylurinstofderivater og deres anvendelse som chloridkanalblokkere

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties